hDR3(2)/hTL1A(3)

Fig.1 Detection of hDR3 expressed on Spleen in 8-10-week-old female WT C57BL/6 and HO hDR3(2) mice.

Fig.2 Detection of TNFSF15 expression in kidney in hTL1A(3) mice by RT-PCR . 

Wild type: only one band at 285 bp with primers F1/R1(mTnfsf15);

Homozygous: only one band at 233 bp with primers F2/R2(hTNFSF15).

Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig.3 Detection of hTL1A and mTL1A expression in plasma  in hTL1A(3) mice by ELISA(n=2). 

Abbr. HO, homozygous; WT, wild type; N.D. not detected.

Note. hTL1A and C57BL/6 mice were i.p. injected with LPS for 24h.

Fig.4 In vivo efficacy assessment of RVT3101, Tulisokibart and Duvakitug in the TBNS-induced acute colitis model of hDR3(2)/hTL1A(3) mice. (A) Body weight change; (B) DAI score. 

In this study, all hDR3/hTL1A mice were randomly divided into experimental and control cohorts groups on Day -1. The treatment groups received intraperitoneal injections of anti-human TL1A antibody RVT-3101 and Tulisokibart (25mpk), the TL1A inhibitor Duvakitug (25mpk) every three days for a total of two doses. The acute colitis model was established in hDR3/hTL1A mice by a single intrarectal injection of 1.5% TNBS on Day 0. Body weight and DAI score were recorded daily. (n=3 males and 2 females per group, 6-8 weeks old, Mean ± SEM, Unpaired t-test, *P<0.05, **P<0.01, ***P<0.0001)

Fig.5 In vivo efficacy assessment of RVT3101, Tulisokibart and Duvakitug in the TBNS-induced acute colitis model of hDR3(2)/hTL1A(3) mice. (A) Colon index; (B) Colon photo.

On Day 5, all mice were sacrificed, and the isolated colons were subjected to weight and photograph. The results demonstrated that, compared with the control group, treatment groups exhibited a significant amelioration of TBNS-induced acute colitis in hDR3/hTL1A mice. (n=3 males and 2 females per group, 6-8 weeks old, Mean ± SEM, Unpaired t-test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)